Anika Therapeutics (NASDAQ:ANIK) Bolsa

Anika Therapeutics

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.

Stock Movers

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADTX

ANAB

ANIK

ANNA

AREB

ASBP

CDLX

ELME

FAMI

HEPA

INTC

NOVA

PATH

SGBX

SNES

STGW

YOSH

Intel designa un nuevo CEO y sus acciones suben con fuerza en el premercado. Descubre qué otros valores destacan hoy.

Las acciones de Intel suben más del 10%; 20 acciones que se están moviendo en el premercado

Anika Therapeutics Inc

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Barrington Research cut Anika Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) price target from $25 to $20. Barrington Research analyst Michael Petusky maintained an Outperform rating. Anika Therapeutics shares closed at $17.11 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/ANIK/analyst-ratings">view this stock</a>.</li>
<li>Truist Securities boosted the price target for Mercury Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) from $49 to $56. Truist Securities analyst Michael Ciarmoli upgraded the stock from Hold to Buy. Mercury Systems shares closed at $42.10 on Wednesday. See how other analysts <a href="https://www.benzinga.com/quote/MRCY/analyst-ratings">view this stock</a>.</li>
<li>Oppenheimer cut Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) price target from $560 to $530. Oppenheimer analyst Brian Schwartz maintained an Outperform rating. Adobe shares closed at $438.60 on Wednesday. <a href="https://www.benzinga.com/quote/ADBE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho slashed the price target for American Homes 4 Rent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMH#NYSE">AMH</a>) from $41 to $37. Mizuho analyst Haendel St. Juste maintained an Outperform rating. American Homes 4 Rent shares closed at $34.99 on Wednesday. <a href="https://www.benzinga.com/quote/AMH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Morgan Stanley cut the price target for UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from $16 to $12. Morgan Stanley analyst Sanjit Singh maintained an Equal-Weight rating. UiPath shares closed at $11.83 on Wednesday. <a href="https://www.benzinga.com/quote/PATH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut Signet Jewelers Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) price target from $65 to $55. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. Signet shares settled at $48.42 on Wednesday. <a href="https://www.benzinga.com/quote/SIG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keefe, Bruyette &amp; Woods raised AXIS Capital Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXS#NYSE">AXS</a>) price target from $115 to $118. Keefe, Bruyette &amp; Woods analyst Meyer Shields maintained an Outperform rating. AXIS Capital shares closed at $91.89 on Wednesday. <a href="https://www.benzinga.com/quote/AXS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) price target from $19 to $25. B of A Securities analyst Vivek Arya upgraded the stock from Underperform to Neutral. Intel shares closed at $20.68 on Wednesday.  <a href="https://www.benzinga.com/quote/INTC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays raised the price target for Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) from $56 to $62. Barclays analyst Lauren Lieberman upgraded the stock from Underweight to Equal-Weight. Molson Coors shares settled at $59.38 on Wednesday. <a href="https://www.benzinga.com/quote/TAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson raised Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) price target from $425 to $450. DA Davidson analyst Gil Luria upgraded the stock from Neutral to Buy. Microsoft shares closed at $383.27 on Wednesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44295828/adobe-intel-and-3-stocks-to-watch-heading-into-thursday">Adobe, Intel And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>

Price Target

Analyst Ratings

ADBE

MRCY

MSFT

Microsoft To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Thursday

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $25 to $20.

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $20

U.S. stock futures fell again on Thursday after a brief respite on Wednesday, following a softer-than-expected inflation print. Futures of all four benchmark indices declined in premarket trading.
President Donald Trump imposed the promised 25% tariffs on steel and aluminum imports on Wednesday. In response, Canada imposed 25% retaliatory tariffs on the U.S. steel imports and raised taxes on other items, whereas the European Union also retaliated with tariffs on American beef, poultry, bourbon, motorcycles, peanut butter, and jeans.
Meanwhile, the 10-year Treasury yield stood at 4.32%, while the two-year yield was at 3.98%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 97% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.38%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.30%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.23%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, dropped in premarket on Thursday. The SPY was down 0.21% to $557.72, and the QQQ also declined 0.31% to $475.43, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Fueled by strong gains in consumer discretionary, information technology, and communication services, U.S. stocks closed mixed on Wednesday.
Indices rose after inflation data revealed a larger-than-expected slowdown, with February&#8217;s Consumer Price Index dipping to 2.8%. Core inflation also dropped more than anticipated, easing from 3.3% to 3.1%.
Tech giants Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) led the charge, while consumer staples and healthcare sectors lagged.
As of Wednesday&#8217;s close, the S&amp;P 500 had fallen 8.92% and the Dow Jones 8.26% from their 52-week highs. The Nasdaq 100 and Nasdaq Composite were still in the correction territory, dropping 11.82% and 12.65%, respectively, from their recent peaks.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.22%</td>
<td>17,648.45</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.49%</td>
<td>5,599.30</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.20%</td>
<td>41,350.93</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.14%</td>
<td>2,026.47</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
&#8220;The opportunity has arrived with the current pullback,&#8221; said Scott Wren, the senior global market strategist at Wells Fargo Advisors. He had been advising the investors to exercise patience and wait for the right time to buy equities.
&#8220;We see the current pullback as an opportunity to add exposure to equities and suggest that clients bring their U.S. Mid-cap exposure up to a favorable (overweight) allocation relative to their strategic (long-term) target weighting. Our large capitalization (SPX-type) rating remains favorable,&#8221; he said.
However, economist Jeremy Siegel warned investors against &#8220;aggressive buying&#8221;.
&#8220;I expect continued volatility, with sentiment swinging on headlines. While there's potential for a rebound, the market valuations are elevated versus history, so there isn't a strong incentive for aggressive buying just yet,&#8221; he said.
According to&nbsp;Alex Tsepaev, the chief strategy officer at B2PRIME Group, the markets have experienced similar or larger corrections nearly every year, indicating this decline could simply reflect normal market fluctuations rather than signaling deeper trouble.
"Investors should watch key economic indicators closely, but a pullback alone isn't necessarily a sign of an impending downturn—it's more likely part of a regular market adjustment," he said.
Despite annual market swings averaging a 16% average drop, the S&amp;P 500 has historically delivered a 10% average annual return since 1928, said Charlie Bilello, the chief market strategist at Creative Planning.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 has returned an average of 10% per year since 1928 despite an average intra-year drawdown of -16%. There&#39;s no upside without occasional downside, no reward without risk. <a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a> Video: <a href="https://t.co/bp8qymBdHZ">https://t.co/bp8qymBdHZ</a> <a href="https://t.co/0hQ48RADUx">pic.twitter.com/0hQ48RADUx</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1900030686108467652?ref_src=twsrc%5Etfw">March 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Thursday:
<ul>
<li>The initial jobless claims data for the week ended March 8 will be released at 8:30 a.m., ET.</li>
</ul>
<ul>
<li>The core and headline producer price index data for February will also be announced at 8:30 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Dollar General Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DG#NYSE">DG</a>) was up 0.60% in premarket on Thursday as it is expected to report before the opening bell. Analysts expect earnings of $1.50 per share on the revenue of $10.26 billion.</li>
</ul>
<ul>
<li>G-III Apparel Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) was 0.04% higher as Wall Street expects it to report earnings of 97 cents per share on the revenue of $807.59 million before the opening bell.</li>
</ul>
<ul>
<li>Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) advanced 0.02% as it is expected to report after the closing bell. Analysts expect earnings of $7.12 per share on revenue of $3.46 billion.</li>
</ul>
<ul>
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) dropped 4.7% as its lower end of the second-quarter outlook was below the market expectations. It expects second-quarter revenue between $5.77 billion to $5.82 billion versus estimates of $5.8 billion. Whereas it expects adjusted earnings of $4.95 to $5 per share versus estimates of $5 per share.</li>
</ul>
<ul>
<li>Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) jumped 9.91% after announcing a new chief executive officer. The company said its board of directors has appointed Lip-Bu Tan, a former member of Intel&#8217;s board of directors, as chief executive officer, effective March 18.</li>
</ul>
<ul>
<li>Aditxt Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) slumped 38.03% after it announced an 1-for-250 reverse stock split which will take place on March 17, 2025, to regain Nasdaq compliance, following a delisting notice.</li>
</ul>
<ul>
<li>Anika Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) plummeted 24.02% after reporting a quarterly loss of $0.03 per share, significantly missing the estimate of a $0.09 gain.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading lower in the early New York session by 0.15% to hover around $67.58 per barrel.
The gold spot index was up by 0.34% to $2,943.35 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was up 0.06% at the 103.674 level.
All Asian markets closed lower on Thursday as Japan's Nikkei 225, South Korea's Kospi, Australia's ASX 200, Hong Kong's Hang Seng, India's S&amp;P BSE Sensex, and China's CSI 300 index declined. European markets were mostly lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44296698/time-to-buy-the-dip-or-wait-till-further-clarity-on-tariffs-heres-what-experts-are-saying-amid-ongoing-market-correction">Time To Buy The Dip Or Wait Till Further Clarity On Tariffs? Here&#8217;s What Experts Are Saying Amid Ongoing Market Correction</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Equities

Market Summary

Futures

Economics

GIII

NVDA

TSLA

ULTA

US Stocks Likely To Open Lower After A Brief Respite: 'Add Exposure To Equities' Amid Pullback, Says Expert

Shares of Intel Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) rose sharply in today's pre-market trading after the company announced <a href="https://www.benzinga.com/news/management/25/03/44291118/intel-stock-rallies-after-company-names-new-ceo-what-to-know">a new chief executive officer.</a>
The company said its board of directors has appointed Lip-Bu Tan, a former member of Intel&#8217;s board of directors, as chief executive officer, effective March 18. Tan will succeed Interim Co-CEOs David Zinsner and Michelle (MJ) Johnston Holthaus.
Intel shares jumped 10.6% to $22.88 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Damon Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) rose 34% to $0.2394 in pre-market trading.</li>
<li>Elme Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELME#NYSE">ELME</a>) gained 29.1% to $21.99 in pre-market trading.</li>
<li>Aspire Biopharma Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) gained 25% to $0.9250 in pre-market trading after falling 7% on Wednesday.</li>
<li>Cardlytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) gained 22.7% to $2.43 in pre-market trading after the company announced financial results for the fourth quarter and full year ended Dec. 31, 2024.</li>
<li>AleAnna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNA#NASDAQ">ANNA</a>) gained 19.2% to $6.08 in pre-market trading after declining 4% on Wednesday.</li>
<li>Safe &amp; Green Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGBX#NASDAQ">SGBX</a>) gained 18.4% to $0.6480 in pre-market trading after the company announced it requested its registration statement on Form S-1 be withdrawn because it decided not to purse the offering and will consider other alternatives.</li>
<li>SenesTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) rose 18% to $2.69 after the company reported better-than-expected Q4 EPS results. Also, the company announced it plans new operating optimization initiatives to reduce expenses and accelerate its path to profitability.</li>
<li>Stagwell Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STGW#NASDAQ">STGW</a>) shares climbed 8.8% to $6.49 in pre-market trading.</li>
<li>Yoshiharu Global Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) gained 7.5% to $16.00 in pre-market after gaining more than 12% on Wednesday.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Aditxt, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADTX#NASDAQ">ADTX</a>) shares fell 39.1% to $0.0346 in pre-market trading after the company announced a 1-for-250 reverse stock split.</li>
<li>Anika Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) dipped 24% to $13.00 in pre-market trading after the company reported fourth-quarter financial results.</li>
<li>Hepion Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) declined 23.5% to $0.0373 in pre-market trading after dipping around 42% on Wednesday.</li>
<li>American Rebel Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) shares fell 21.3% to $0.2578 in pre-market trading after gaining around 8% on Wednesday.</li>
<li>Sunnova Energy International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOVA#NYSE">NOVA</a>) fell 18.4% to $0.2997 in pre-market trading after dipping 14% on Wednesday. The company recently announced it appointed Paul Mathews as President and CEO.</li>
<li>UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) fell 16.7% to $9.85 in pre-market trading after the company reported a fourth-quarter revenue miss and issued first-quarter revenue guidance below estimates.</li>
<li>Farmmi, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAMI#NASDAQ">FAMI</a>) fell 15.9% to $0.1698 in today's pre-market trading after the company reported a 1-for-12 share consolidation.</li>
<li>SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) fell 13.6% to $16.68 in pre-market trading after the company reported fourth-quarter results.</li>
<li>American Eagle Outfitters, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) shares dipped 10.9% to $10.20 in pre-market trading following fourth-quarter results.</li>
<li>AnaptysBio, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANAB#NASDAQ">ANAB</a>) shares tumbled 6.8% to $16.50 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44274110/top-2-industrials-stocks-that-may-collapse-in-march">Top 2 Industrials Stocks That May Collapse In March</a></li>
</ul>

Why Intel Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

<h3>Companies Reporting Before The Bell</h3>
• EHang Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EH#NASDAQ">EH</a>) is projected to report quarterly loss at $0.07 per share on revenue of $23.36 million. 
• Hello Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) is projected to report quarterly earnings at $0.21 per share on revenue of $365.05 million. 
• Chicago Atlantic Real (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFI#NASDAQ">REFI</a>) is estimated to report quarterly earnings at $0.56 per share on revenue of $14.19 million. 
• Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is expected to report earnings for its fourth quarter. 
• Upland Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $67.84 million. 
• VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly earnings at $0.03 per share on revenue of $284.88 million. 
• Vera Bradley (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRA#NASDAQ">VRA</a>) is likely to report quarterly earnings at $0.06 per share on revenue of $107.94 million. 
• Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $200.59 million. 
• Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $1.15 billion. 
• Vivid Seats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEAT#NASDAQ">SEAT</a>) is expected to report quarterly earnings at $0.06 per share on revenue of $194.15 million. 
• OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) is estimated to report quarterly earnings at $0.27 per share on revenue of $30.36 million. 
• Navigator Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVGS#NYSE">NVGS</a>) is expected to report quarterly earnings at $0.32 per share on revenue of $120.87 million. 
• ABM Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABM#NYSE">ABM</a>) is projected to report quarterly earnings at $0.78 per share on revenue of $2.09 billion. 
• Smith Douglas Homes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SDHC#NYSE">SDHC</a>) is likely to report quarterly earnings at $0.45 per share on revenue of $265.85 million. 
• Amarin Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) is expected to report quarterly loss at $0.03 per share on revenue of $32.37 million. 
• ZIM Integrated Shipping (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) is expected to report quarterly earnings at $3.49 per share on revenue of $2.02 billion. 
• Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is projected to report quarterly earnings at $0.13 per share on revenue of $161.60 million. 
• National Energy Services (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $339.84 million. 
• iRobot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRBT#NASDAQ">IRBT</a>) is expected to report quarterly loss at $1.73 per share on revenue of $171.00 million. 
• Ondas Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONDS#NASDAQ">ONDS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $5.75 million. 
• BingEx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLX#NASDAQ">FLX</a>) is expected to report earnings for its fourth quarter. 
• InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) is likely to report quarterly loss at $0.19 per share on revenue of $1.82 million. 
• United Homes Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UHG#NASDAQ">UHG</a>) is estimated to report earnings for its fourth quarter. 
• Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $24.15 million. 
• MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) is expected to report quarterly loss at $0.19 per share on revenue of $61.57 million. 
<h3>Companies Reporting After The Bell</h3>
• Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $110.28 million. 
• KLX Energy Services Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLXE#NASDAQ">KLXE</a>) is expected to report quarterly loss at $0.80 per share on revenue of $168.90 million. 
• Algoma Steel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTL#NASDAQ">ASTL</a>) is expected to report earnings for its third quarter. 
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is projected to report quarterly loss at $0.25 per share on revenue of $129.53 million. 
• Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) is estimated to report earnings for its fourth quarter. 
• Legacy Housing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGH#NASDAQ">LEGH</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $44.59 million. 
• Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) is expected to report quarterly loss at $0.19 per share on revenue of $36.66 million. 
• Montauk Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTK#NASDAQ">MNTK</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $56.32 million. 
• Ellington Credit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EARN#NYSE">EARN</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $9.65 million. 
• FreightCar America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIL#NASDAQ">RAIL</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $152.02 million. 
• PHX Minerals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHX#NYSE">PHX</a>) is estimated to report quarterly earnings at $0.03 per share on revenue of $8.93 million. 
• Crown Castle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCI#NYSE">CCI</a>) is expected to report quarterly earnings at $1.82 per share on revenue of $1.64 billion. 
• SentinelOne (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) is estimated to report quarterly loss at $0.21 per share on revenue of $222.33 million. 
• ContextLogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGC#NASDAQ">LOGC</a>) is likely to report earnings for its fourth quarter. 
• UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $425.34 million. 
• SenesTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNES#NASDAQ">SNES</a>) is estimated to report quarterly loss at $1.50 per share on revenue of $710 thousand. 
• RCM Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCMT#NASDAQ">RCMT</a>) is expected to report quarterly earnings at $0.83 per share on revenue of $79.00 million. 
• Beauty Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKIN#NASDAQ">SKIN</a>) is projected to report quarterly loss at $0.09 per share on revenue of $77.45 million. 
• Fathom Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTHM#NASDAQ">FTHM</a>) is projected to report quarterly loss at $0.17 per share on revenue of $84.70 million. 
• Cardlytics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) is estimated to report quarterly loss at $0.20 per share on revenue of $63.63 million. 
• Biote (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTMD#NASDAQ">BTMD</a>) is likely to report quarterly earnings at $0.17 per share on revenue of $51.20 million. 
• Limoneira (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMNR#NASDAQ">LMNR</a>) is projected to report quarterly loss at $0.17 per share on revenue of $40.70 million. 
• Calavo Growers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGW#NASDAQ">CVGW</a>) is expected to report quarterly earnings at $0.29 per share on revenue of $161.55 million. 
• KORU Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRMD#NASDAQ">KRMD</a>) is likely to report quarterly loss at $0.02 per share on revenue of $8.89 million. 
• American Eagle Outfitters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEO#NYSE">AEO</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $1.60 billion. 
• Berry Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRY#NASDAQ">BRY</a>) is expected to report quarterly earnings at $0.15 per share on revenue of $173.00 million. 
• Phreesia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) is projected to report quarterly loss at $0.19 per share on revenue of $108.91 million. 
• Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) is projected to report quarterly earnings at $4.97 per share on revenue of $5.66 billion. 
• electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) is expected to report quarterly loss at $0.34 per share on revenue of $7.29 million. 
• AudioEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) is expected to report quarterly earnings at $0.18 per share on revenue of $9.73 million. 
• BGSF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BGSF#NYSE">BGSF</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $67.65 million. 
• CI&amp;T (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CINT#NYSE">CINT</a>) is projected to report earnings for its fourth quarter. 
• Companhia Siderurgica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SID#NYSE">SID</a>) is projected to report quarterly loss at $0.09 per share on revenue of $1.94 billion. 
• Performant Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHLT#NASDAQ">PHLT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $34.15 million. 
• Urgently (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULY#NASDAQ">ULY</a>) is expected to report earnings for its fourth quarter. 
• Assertio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASRT#NASDAQ">ASRT</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $28.67 million. 
• Quest Resource Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRHC#NASDAQ">QRHC</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $73.63 million. 
• CPS Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPSH#NASDAQ">CPSH</a>) is estimated to report earnings for its fourth quarter. 
• Kewaunee Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KEQU#NASDAQ">KEQU</a>) is expected to report earnings for its third quarter. 
• Zedge (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZDGE#AMEX">ZDGE</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $7.71 million. 
• NextNav (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NN#NASDAQ">NN</a>) is expected to report quarterly loss at $0.14 per share on revenue of $1.73 million. 
• Monogram Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRM#NASDAQ">MGRM</a>) is estimated to report earnings for its fourth quarter. 
• Fossil Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOSL#NASDAQ">FOSL</a>) is likely to report earnings for its fourth quarter. 
• Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $29.00 million. 
• Aris Mining (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMN#AMEX">ARMN</a>) is likely to report earnings for its fourth quarter. 
• Brilliant Earth Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRLT#NASDAQ">BRLT</a>) is expected to report quarterly earnings at $0.00 per share on revenue of $116.82 million. 
• Tilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TLYS#NYSE">TLYS</a>) is expected to report quarterly loss at $0.29 per share on revenue of $159.90 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEYE

AMRN

ARCO

ARIS

ARMN

ASRT

ASTL

BGSF

BRLT

BTMD

CINT

CMTL

CPSH

CVGW

EARN

ECOR

FOSL

FTHM

HBIO

IRBT

KEQU

KLXE

KRMD

LEGH

LMNR

LOGC

MGRM

MNTK

MOMO

NESR

NKTR

NSPR

NVGS

ONDS

OPRX

PHLT

QRHC

RAIL

RCMT

REFI

SDHC

SEAT

SKIN

TLYS

UPLD

VNET

VSTA

ZDGE

Earnings Scheduled For March 12, 2025

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and lowers the price target from $37 to $25.

Barrington Research Maintains Outperform on Anika Therapeutics, Lowers Price Target to $25

WIIM

Anika Therapeutics shares are trading lower after the company reported worse-than-expected Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) stock increased by 88.0% to $1.76 during Thursday's regular session. The company's market cap stands at $9.7 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock increased by 27.24% to $13.03. The market value of their outstanding shares is at $15.0 million. </li>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) stock increased by 22.59% to $7.0. The market value of their outstanding shares is at $593.5 million. </li>
<li>Aerovate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVTE#NASDAQ">AVTE</a>) stock rose 22.32% to $2.68. The company's market cap stands at $77.3 million. </li>
<li>MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) shares moved upwards by 22.05% to $6.95. The company's market cap stands at $1.0 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock rose 19.08% to $3.12. The market value of their outstanding shares is at $6.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) stock decreased by 69.1% to $0.6 during Thursday's regular session. The market value of their outstanding shares is at $2.9 million. </li>
<li>Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) stock decreased by 28.39% to $17.68. The company's market cap stands at $257.8 million. The company's, Q3 earnings came out today. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) shares fell 24.95% to $0.07. The company's market cap stands at $3.8 million. </li>
<li>CalciMedica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALC#NASDAQ">CALC</a>) stock declined by 24.2% to $3.64. The market value of their outstanding shares is at $39.1 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) shares fell 23.13% to $4.76. The company's market cap stands at $325.4 million. As per the news, the Q3 earnings report came out today. </li>
<li>Vaccinex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCNX#NASDAQ">VCNX</a>) stock fell 21.34% to $3.17. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

AVTE

AVXL

BFRI

CALC

CMPS

MDXG

MTNB

VCNX

XCUR

12 Health Care Stocks Moving In Thursday's Intraday Session

The sale of the Company's Arthrosurface business to Phoenix Brio, Incorporated closed today, October 31, 2024. The Company received consideration of $10 million in the form of a ten year non-interest bearing promissory note for $7 million, and an estimated $3 million of additional consideration subject to the sales performance of Arthrosurface.

Asset Sales

Anika Closes Divestiture Of Its Arthrosurface Business And Intention To Divest Of Parcus Medical Business

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.01) by 2400 percent. The company reported quarterly sales of $38.75 million which missed the analyst consensus estimate of $42.08 million by 7.91 percent. This is a 6.54 percent decrease over sales of $41.47 million the same period last year.

Earnings Misses

Anika Therapeutics Q3 2024 Adj EPS $(0.25) Misses $(0.01) Estimate, Sales $38.75M Miss $42.08M Estimate

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) will release its quarterly earnings report on Thursday, 2024-10-31. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Anika Therapeutics to report an earnings per share (EPS) of $-0.01.
Anticipation surrounds Anika Therapeutics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.12, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Anika Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.05</td>
<td>-0.19</td>
<td>-0.26</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.17</td>
<td>0.09</td>
<td>0.05</td>
<td>0</td>
</tr>
<tr>
<td>Price Change %</td>
<td>0.0%</td>
<td>-11.0%</td>
<td>-3.0%</td>
<td>11.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730315032_0.png" alt="eps graph" />
<a href="https://www.benzinga.com/quote/ANIK/earnings">To track all earnings releases for Anika Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What's Next: Anika Therapeutics's Earnings Preview

Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Outperform and maintains $37 price target.

Barrington Research Maintains Outperform on Anika Therapeutics, Maintains $37 Price Target

Fiscal 2024 Guidance
Anika continues to expect that revenue for fiscal 2024 will be in the range of $168 to $173 million, representing growth of 1% to 4% compared to 2023.
&nbsp;
Revenue ranges by product family are:
<ul>
<li>OA Pain Management of $102 to $104 million, up 0% to 2%</li>
<li>Joint Preservation and Restoration of $58 to $60.5 million, up 6% to 10%</li>
<li>Non-Orthopedic of $8 to $8.5 million, down 14% to 19%</li>
</ul>

Guidance

Anika Therapeutics Affirms FY2024 Sales Guidance Of $168M-$173M Vs, $170.84M Estimate

Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.05 by 240 percent. This is a 45.16 percent decrease over earnings of $0.31 per share from the same period last year. The company reported quarterly sales of $41.920 million which missed the analyst consensus estimate of $42.099 million by 0.43 percent. This is a 5.38 percent decrease over sales of $44.302 million the same period last year.

Earnings Beats

Anika Therapeutics Q2 2024 Adj. EPS $0.17 Beats $0.05 Estimate, Sales $41.920M Miss $42.099M Estimate

Integrity and its complete arthroscopic instrumentation platform are now fully available in the U.S., expanding Anika's proprietary hyaluronic acid (HA) regenerative portfolio
Over 300 surgeries completed during the limited market release, highlighting the growing interest and commercial demand across a wide range of tendon repairs

Biotech

General

Anika Therapeutics Announces Full Market Release Of Integrity Implant System

In the latest quarter, 4 analysts provided ratings for Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Anika Therapeutics, presenting an average target of $30.0, a high estimate of $37.00, and a low estimate of $22.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1716998434_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Anika Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Raises</td>
<td>Outperform</td>
<td>$37.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>George Sellers</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$22.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Anika Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Anika Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Anika Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Anika Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ANIK/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Anika Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Anika Therapeutics's Background</h2>
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
<h3>Anika Therapeutics's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Anika Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 6.85%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Anika Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -11.14% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Anika Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.15%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Anika Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of -1.69%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Anika Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights

Stephens &amp; Co. analyst George Sellers reiterates Anika Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIK#NASDAQ">ANIK</a>) with a Equal-Weight and maintains $24 price target.

Reiteration

Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $24 Price Target

Buybacks

Anika Authorizes $40M Share Repurchase Program

Anika Enters Into Cooperation Agreement With Caligan Partners; Appoints Joseph Capper And William Jellison To Board Of Directors

Press Releases

Anika Reports Third Quarter 2024 Financial Results

Arthrosurface Returns to it Roots Following Divestiture from Anika Therapeutics

Anika To Participate in December 2024 Investor Conferences

Events

Sidoti Events, LLC's Virtual December Small-Cap Conference

Anika To Participate in 43rd Annual J.P. Morgan Healthcare Conference

Anika To Present at the Canaccord Genuity 2025 Musculoskeletal Conference

Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025

Comments

Anika Therapeutics

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL